Axonics Inc. (NASDAQ: AXNX) stock fell -2.50% on Friday to $69.40 against a previous-day closing price of $71.18. With 2.6 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.59 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $69.45 whereas the lowest price it dropped to was $66.00. The 52-week range on AXNX shows that it touched its highest point at $79.81 and its lowest point at $38.41 during that stretch. It currently has a 1-year price target of $70.62. Beta for the stock currently stands at 0.45.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AXNX was up-trending over the past week, with a rise of 7.55%, but this was up by 15.21% over a month. Three-month performance surged to 20.19% while six-month performance rose 39.44%. The stock gained 4.13% in the past year, while it has gained 23.93% so far this year. A look at the trailing 12-month EPS for AXNX yields -1.81 with Next year EPS estimates of -1.62. For the next quarter, that number is -0.54. This implies an EPS growth rate of -25.20% for this year and 23.50% for next year.
Float and Shares Shorts:
At present, 45.14 million AXNX shares are outstanding with a float of 42.65 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.2 million, which was 8.91% higher than short shares on Jun 14, 2022. In addition to Mr. Raymond W. Cohen as the firm’s CEO & Director, Mr. Danny L. Dearen serves as its Pres & CFO.
Through their ownership of 111.22% of AXNX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 63.22% of AXNX, in contrast to 38.10% held by mutual funds. Shares owned by individuals account for 35.97%. As the largest shareholder in AXNX with 6.19% of the stake, BlackRock Fund Advisors holds 2,913,351 shares worth 2,913,351. A second-largest stockholder of AXNX, The Vanguard Group, Inc., holds 2,698,798 shares, controlling over 5.73% of the firm’s shares. Bellevue Asset Management AG is the third largest shareholder in AXNX, holding 2,049,205 shares or 4.35% stake. With a 3.61% stake in AXNX, the CS Invt. Fds. 2 – is the largest stakeholder. A total of 1,700,000 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.50% of AXNX stock, is the second-largest Mutual Fund holder. It holds 1,178,104 shares valued at 66.76 million. iShares Russell 2000 ETF holds 2.22% of the stake in AXNX, owning 1,045,715 shares worth 59.26 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AXNX since 8 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AXNX analysts setting a high price target of $87.00 and a low target of $60.00, the average target price over the next 12 months is $77.38. Based on these targets, AXNX could surge 25.36% to reach the target high and fall by -13.54% to reach the target low. Reaching the average price target will result in a growth of 11.5% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AXNX will report FY 2022 earnings on 03/08/2023. Analysts have provided yearly estimates in a range of -$1.37 being high and -$2.10 being low. For AXNX, this leads to a yearly average estimate of -$1.80. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Axonics Inc. surprised analysts by $0.08 when it reported -$0.47 EPS against a consensus estimate of -$0.55. The surprise factor in the prior quarter was $0.13. Based on analyst estimates, the high estimate for the next quarter is -$0.39 and the low estimate is -$0.53. The average estimate for the next quarter is thus -$0.48.
Summary of Insider Activity:
Insiders traded AXNX stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 5,250 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 45 over the past year. The total number of shares bought during that period was 442,803 while 401,572 shares were sold.